Resolvin E1 (RvE1) is an E-series resolvin biosynthesized from EPA via 5-LOX and acetylated COX-2 enzymes during active resolution of inflammation. It signals primarily through ERV1/ChemR23 receptor and secondarily through Leukotriene B4 receptor BLT1 as a partial agonist, actively terminating neutrophil infiltration, enhancing macrophage efferocytosis, and promoting tissue regeneration.
Imagine an emergency response after a building fire. The fire trucks (neutrophils) have finished dousing the flames and now need to leave so the cleanup crew can work. RvE1 is like the site supervisor who shows up with two clipboards—one for the fire department and one for the cleanup team.
With the first clipboard (ERV1/ChemR23), she tells the fire trucks "Stop coming, we have enough water damage already"—blocking >90% of additional emergency vehicles from flooding the scene. With the second clipboard (BLT1 receptor), she redirects a few fire trucks that ignored the first signal, acting as a partial blocker at the dispatch center.
Meanwhile, she hands the cleanup crew (macrophages) specialized vacuum equipment that makes them 3-4 times better at removing debris (dead cells). She also calls in the construction team (fibroblasts) and tells them "Start rebuilding, the emergency phase is over." This is the transition from demolition to reconstruction—from inflammation to resolution. But here's the key: she can only do her job if the right raw materials were delivered to the site beforehand (EPA from fish oil), and if the factory that makes her clipboard forms (5-LOX and acetylated COX-2) is functioning properly.
RvE1 biosynthesis occurs through Lipid mediator class switching when acute inflammation transitions to active resolution:
Biosynthesis pathway:
- EPA (C20:5n-3) released from membrane phospholipids by phospholipase A2
- 5-LOX converts EPA to 5S-hydroperoxy-EPA (5-HpEPE)
- In the presence of aspirin or inflammatory signals, COX-2 becomes acetylated (acetylated COX-2)
- Acetylated COX-2 performs 15-epimerization → 5S,15R-diHEPE
- Alternatively, 15-LOX (in epithelial cells or during cell-cell interactions) can produce the same intermediate
- Final conversion to 5S,12R,18R-trihydroxy-EPA = RvE1
Receptor signaling:
-
Primary pathway (ERV1/ChemR23): RvE1 binds ERV1/ChemR23 (Kd ~11 nM) → Gαi protein activation → decreased cAMP → reduced NF-κB translocation → inhibition of neutrophil chemotaxis (blocks CD11b/CD18 integrin upregulation) → enhanced macrophage phagocytosis via Rac1/Akt pathway → increased efferocytosis (3-4 fold increase in apoptotic cell clearance)
-
Secondary pathway (BLT1): RvE1 acts as partial agonist at Leukotriene B4 receptor BLT1 (Kd ~45 nM) → competitive inhibition of pro-inflammatory LTB4 signaling → reduced calcium mobilization → dampened neutrophil activation
Downstream effects:
- ↓ Interleukin-6 production (50-70% reduction at 10-100 nM RvE1)
- ↓ TNF-α secretion (40-60% reduction)
- ↓ NF-κB activation in macrophages and epithelial cells
- ↑ Macrophage-mediated debris clearance
- ↑ Tissue regeneration signals (promotes fibroblast migration and collagen synthesis)
- ↓ Pain sensitivity (modulates TRPV1 and dorsal root ganglia excitability)
graph TD
EPA[EPA from membrane] --> LOX5[5-LOX]
LOX5 --> HpEPE[5-HpEPE]
HpEPE --> COX2[Acetylated COX-2 or 15-LOX]
COX2 --> diHEPE[5S,15R-diHEPE]
diHEPE --> RvE1[RvE1]
RvE1 --> ERV1[ERV1/ChemR23 receptor]
RvE1 --> BLT1[BLT1 receptor partial agonist]
ERV1 --> Gi["Gαi activation"]
Gi --> cAMP["↓ cAMP"]
cAMP --> NFkB["↓ NF-κB"]
Gi --> Rac1["↑ Rac1/Akt"]
NFkB --> Neutrophil["↓ Neutrophil infiltration 90%"]
Rac1 --> Effero["↑ Efferocytosis 3-4x"]
BLT1 --> LTB4block[Blocks LTB4 pro-inflammatory signal]
LTB4block --> Calcium["↓ Ca2+ mobilization"]
Effero --> IL6["↓ IL-6 50-70%"]
Effero --> TNF["↓ TNF-α 40-60%"]
Effero --> Regen["↑ Tissue regeneration"]
RvE1 represents a critical intervention point in the resolution phase of inflammation, making it clinically relevant for any chronic inflammatory states where resolution is incomplete or stalled.
Patient populations:
Metamodel connections:
- Evolutionary mismatch: Modern Western diets provide omega-6:omega-3 ratios of 15-20:1 (ancestral ~1-2:1), creating substrate deficiency for RvE1 synthesis. Humans lack dietary EPA but obtain it only from marine sources or inefficient conversion from ALA (<5% efficiency in most individuals).
- Selfish immune system: Prolonged inflammation without resolution allows immune cells to maintain high metabolic activity and nutrient uptake, but at organism-level cost. RvE1 actively terminates this state.
- 5+2 metamodel: RvE1 connects all systems—immune (neutrophil regulation), metabolic (EPA substrate, COX-2 enzymatic function), neuroendocrine (pain modulation, HPA-axis feedback via reduced inflammatory cytokines)
Clinical thresholds and biomarkers:
- Effective concentrations in experimental models: 10-100 nM
- Plasma RvE1 in healthy individuals: ~50-200 pg/mL (varies by EPA status)
- Omega-3 index <4% correlates with insufficient substrate for RvE1 synthesis
- Resolution interval (R_i) prolonged when RvE1 production is deficient
- Ψ_max (peak PMN infiltration) remains elevated without adequate RvE1 signaling
Intervention implications:
- EPA supplementation (1-2g/day) specifically supports RvE1 synthesis (vs DHA which produces D-series resolvins)
- Low-dose aspirin (75-100 mg) triggers aspirin-acetylated COX-2 pathway, enhancing RvE1 production (aspirin-triggered resolvins)
- Address enzymatic bottlenecks: ensure adequate 5-LOX function (zinc-dependent) and avoid COX-2 inhibitors during resolution phase
- Timing matters: COX-2 inhibition (NSAIDs) during acute inflammation blocks prostaglandin production appropriately, but during resolution phase (12-72 hours post-injury) it prevents RvE1 synthesis
- Consider exogenous RvE1 analogs (under investigation) for severe resolution failure states
- E-series resolvin derived from EPA (C20:5n-3), distinct from D-series resolvins produced from DHA
- Primary receptor ERV1/ChemR23 has Kd ~11 nM; secondary receptor BLT1 has Kd ~45 nM (partial agonist activity)
- Reduces neutrophil migration by >90% in experimental peritonitis models at 100 nM concentration
- Enhances macrophage efferocytosis 3-4 fold via Rac1/Akt pathway activation
- Biosynthesis requires both substrate (EPA) availability and enzymatic competence (5-LOX, acetylated COX-2 or 15-LOX)
- Aspirin triggers alternative biosynthetic pathway via COX-2 acetylation (aspirin-triggered Resolvins)
- Half-life in vivo ~30-60 minutes, requiring sustained biosynthesis during resolution phase
- Also signals through Leukotriene B4 receptor BLT1 as competitive antagonist of pro-inflammatory LTB4
- Reduces Interleukin-6 secretion 50-70% and TNF-α 40-60% in activated macrophages
- Discovered by Charles Serhan's group at Harvard in 2000 as part of Specialized pro-resolving mediators (SPMs) family
- Inactivated by oxidative metabolism (cytochrome P450) and dehydrogenation (15-hydroxyprostaglandin dehydrogenase)
- Clinical deficiency states: inadequate EPA intake, 5-LOX polymorphisms, excessive COX-2 inhibition during resolution phase, chronic oxidative stress damaging biosynthetic enzymes
- Specialized pro-resolving mediators (SPMs) — founding member of SPM family discovered in resolution pharmacology research
- Resolvins — E-series subfamily derived from EPA, contrasts with D-series from DHA
- EPA — obligate dietary substrate; humans cannot synthesize EPA de novo
- Lipid mediator class switching — process enabling transition from pro-inflammatory eicosanoid production to RvE1 synthesis
- COX-2 — when acetylated by aspirin or inflammatory signals, becomes biosynthetic enzyme for RvE1
- 5-LOX — initiating enzyme converting EPA to 5-HpEPE intermediate
- Efferocytosis — RvE1 enhances this macrophage clearance function 3-4 fold via Rac1/Akt pathway
- Ψ_max (peak PMN infiltration) — RvE1 actively reduces this resolution index by blocking neutrophil chemotaxis
- Resolution interval (R_i) — shortened when RvE1 signaling is intact
- Leukotriene B4 — RvE1 acts as partial agonist at LTB4 receptor BLT1, competitively blocking pro-inflammatory signaling
- NF-κB — RvE1 reduces nuclear translocation via Gαi-cAMP pathway
- Interleukin-6 — production decreased 50-70% by RvE1 signaling in macrophages
- TNF-α — secretion reduced 40-60% by RvE1 in activated immune cells
- Neutrophil — primary target cell type; RvE1 blocks CD11b/CD18 integrin upregulation preventing tissue infiltration
- Inflammation — RvE1 actively terminates the inflammatory phase rather than passively decaying
- Omega-3 fatty acids — EPA is essential omega-3 precursor with <5% conversion efficiency from plant-based ALA
- Aspirin-triggered resolvins — aspirin acetylation of COX-2 enhances RvE1 biosynthesis pathway
- Resolution — RvE1 is pharmacological driver of active resolution, not merely anti-inflammatory
- Macrophage Polarization — RvE1 promotes M2-like phenotype with enhanced phagocytic and tissue-repair functions
- Chronic inflammation — deficiency in RvE1 synthesis contributes to failure of inflammation to resolve
- Inflammatory bowel disease — mucosal RvE1 levels inversely correlate with disease activity in Crohn's and colitis
- Periodontal disease — local RvE1 application shows promise in accelerating gingival healing
- Pain — RvE1 reduces neuropathic and inflammatory pain via modulation of TRPV1 and dorsal root ganglia excitability
- Obesity — adipose tissue produces insufficient RvE1 despite high inflammation, contributing to metabolic dysfunction
- Type 2 Diabetes — impaired resolution via RvE1 deficiency linked to persistent insulin resistance in adipose tissue
- 15-LOX — alternative biosynthetic enzyme in epithelial cells during cell-cell interactions
- Acute inflammatory response — RvE1 production marks transition from acute inflammation to resolution phase
- SPM metabolic inactivation — RvE1 degraded by cytochrome P450 and 15-hydroxyprostaglandin dehydrogenase, limiting duration of action
This concept appears in: